Topics

FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC

19:00 EST 3 Dec 2019 | Cancer Networks

The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

Original Article: FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...